Circulating microRNA-21 as Stable Blood-Based Markers for Patients With ISR After PCI
DOI:
https://doi.org/10.1532/hsf.3245Keywords:
In-stent restenosis, Percutaneous coronary interention, MiR-21, Intravascular ultrasound, Inflammation, proliferation, Ischemic heart diseaseAbstract
It recently has been reported that the in-stent restenosis (ISR) of expanded area after percutaneous coronary intervention (PCI) within six months can become a serious postoperative complication. A real-time quantitative PCR was used to analyze the expression of serum miR-21 in 33 ISR and 37 non-ISR patients after PCI. Expression of miR-21 was significantly higher in the ISR group compared with that in the NISR group, and a similar trend also occurred in factor- (TNF-α) level, Interleukin -6 (IL-6) level, and plaque area (PLA). However, a contrary trend occurred in the external elastic membrane area (EEM) and minimal lumen area (MLA). This study suggests that the increased expression of serum miR-21 is related to ISR after PCI, and miR-21 can be a new predictor of ISR.
References
Alraies MC, Darmoch F, Tummala R, Waksman R. 2017. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 8:640–651.
Bentwich I, Avniel A, Karov Y, et al. 2005. Identification of hundreds of conserved and nonconserved human microRNAs, Nat Genet. 37,766-770.
Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G, Voelker W. 2003. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J. 145:693–699.
Cai X, Hagedorn CH, Cullen BR. 2004. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs, RNA. 10, 1957- 1966.
Cao YY, Chen ZW, Gao YH, Wang XX, Ma JY, Chang SF, Qian JY, Ge JB. 2015. Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction. Chin Med J (Engl). 23: 3211–3218.
Casscells W, Roberts R, Towbin JA. 1994. Mechanisms of restenosis. Texas Heart Inst J. 21:68–77.
Chen ZW, Qian JY, Ma JY, Chang SF, Yun H, Jin H, et al. 2014. TNF-a-induced cardiomyocyte apoptosis contributes to cardiac dysfunction after coronary microembolization in mini-pigs. J Cell Mol Med. 18: 1953–1963.
Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. 2003. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 108: 512–515.
Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. 2003. Inflammation and restenosis: implications for therapy. Ann Med. 35:523–531.
Drachman DE, Simon DI. 2005. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep. 7:44–49.
Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. 2010. Circulating microRNAs in patients with coronary artery disease. Circ Res. 107:677–684.
Fichtlscherer S, Zeiher AM, Dimmeler S. 2011. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 31:2383–2390.
Fujita S, Ito T, Mizutani T, et a1. 2008. MiR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. JMol Biol. 378, 492-504.
Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. 2000. Interleukin 6 expression in coronary circulation after coronary angioplasty as risk factor for restenosis. Heart. 84:83–87.
Huang W, Tian SS, Hang PZ, Sun C, Guo J, Du ZM. 2016. Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice. Mol Ther Nucleic Acids. 3:e296.
Ikeda U, Ito T, Shimada K. 2001. Interleukin-6 and acute coronary syndrome. Clinic Cardiol. 24:701–704.
Jansen F, Schäfer L, Wang H, Schmitz T, Flender A, Schueler R, et al. 2017. Kinetics of Circulating MicroRNAs in Response to Cardiac Stress in Patients With Coronary Artery Disease. J Am Heart Assoc. 8:e005270.
Ji R, Cheng Y, Yue J, et a1. 2007. MicroRNA expression signature and antisense-mediated epletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 100, 1579-1588.
Kim MS, Dean LS. 2011. In-Stent Restenosis. Cardiovasc Ther. 29:190– 8.
Lagos-Quintana M, Rauhut R, Yalcin A, et a1. 2002. Identification of tissue specific micmRNAs from mouse, Curr Biol 12:735-739.
Li-Sha G, Peng C, Yue-Chun L. 2015. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review. BMC Cardiovasc Disord. 15:101.
Liang H, Zhang C, Ban T, et a1. 2012. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int JBiochem Cell Bio. l44:2152- 2160.
Libby P, Simon DI, Rogers C. 2003. Inflammation and artery injury. In: Topol E, editor. Textbook of interventional cardiology. Philadelphia: Saunders. pp. 381–389.
Lindsey BD, Martin KH, Jiang X, Dayton PA. 2016. Adaptive windowing in contrast-enhanced intravascular ultrasound imaging. Ultrasonics. 70:123–135.
Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, Qiao C. 2016. Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiacmiRNA-21 expression, Akt and the Bcl 2/Bax pathway. Mol Med Rep. 5:4216-4222.
Maehara A, Mintz GS, Weissman NJ. 2009. Advances in intravascular imaging. Circ Cardiovasc Interv. 2:482–490.
Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. 2001. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 37:1478–1492.
Mitchell PS, Parkin RK, Kroh EM, et a. 2008. Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci USA. 105:10513- 10518.
Pleva L, Kovarova P, Faldynova L, Plevova P, Hilscherova S, Zapletalova J, Kusnierova P, Kukla P. 2015. The rs1803274 polymorphism of the BCHE gene is associated with an increased risk of coronary in-stent restenosis. BMC Cardiovasc Disord. 15:135.
Qiang S, checked by Lang L. 2013. The research progress of relationship between microRNA-21 and ischemic heart disease. Chin Circ. 28,390-392.
Qin Y, Yu Y, Dong H, et a1. 2012. MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis, Int J Med Sci. 9:413-423.
Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. 2011. Fiveyear clinical and angiographic outcomes of a randomized comparison of sirolimuseluting and paclitaxeleluting stents: results of the SirolimusEluting Versus PaclitaxelEluting Stents for Coronary Revascularization LATE trial. Circulation 123:28192828.
Ren Y, Chen KJ, Ruan XM. 2008. [Systematic review of randomized controlled trials on preventing and treating restenosis after percutaneous coronary intervention with Chinese medicine]. [Article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 28: 597–601.
Roy S, Khanna S, Hussain S-RA, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK. 2009. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 82:21–29.
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King III SB, Loop FD, et al. 1988. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on the Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation. 2:486–502.
Sabatel C, Malvaux L, Bovy N. et a1. 2011. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. Plos One. 6:e16979.
Schillinger M, Minar E. 2005. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag. 1:73–78.
Schulz R, Aker S, Belosjorow S, Heusch G. 2004. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol. 99: 8– 11.
Shen XH, Han YJ, Zhang DX, Cui XS, Kim NH. 2009. A link between the Interleukin-6/Stat3 anti-apoptotic pathway and microRNA-21 in preimplantation mouse embryos. Mol Reprod Dev. 76: 854–862.
Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, et al. 2007. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: Progressive contractile dysfunction versus delayed protection against infarction. Circ Res. 100:140–146.
Small EM, Olson EN. 2011. Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342.
Song J, Hu B, Qu H, et a1. 2012. Mechanical stretch modulates microRNA 21 expression, participating in proliferation and apeptosis in cultured human aortic smooth muscle cells, Plos One. 7:e47657.
Szkodzinski J, Blazelonis A, Wilczek K, Hudzik B, Romanowski W, Gasior M, Wojnar R, Lekston A, Polonski L, Zubelewicz-Szkodzinska B. 2009. The role of interleukin-6 and transforming growth factor-β1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol. 22: 493–500.
Wang XW, Zhang C, Lee KC, He XJ, Lu ZQ, Huang C. 2017. Adenovirus-Mediated Gene Transfer of microRNA-21 Sponge Inhibits Neointimal Hyperplasia in Rat Vein GraftsInt J Biol Sci. 10, 1309–1319.
Xu L, Xu Q, Li X, Zhang X. 2017. MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-α. Mol Med Rep. 4:4659– 4663.
Yang SJ, Zhang Y, Liu Y. 2015. Research on expression of miRNA-21 in the peripheral blood of coronary heart disease and its clinical significance. Zhong Guo Ying Yong Sheng Li Xue Za Zhi. 2:127- 31.
